用替加环素治疗产超广谱β-内酰胺酶大肠埃希菌引起的复发性泌尿道感染。
Treatment with tigecycline of recurrent urosepsis caused by extended-spectrum-beta-lactamase-producing Escherichia coli.
作者信息
Krueger Wolfgang A, Kempf Volkhard A J, Peiffer Manou, Nagele Udo, Unertl Klaus E, Schroeder Torsten H
机构信息
Tübingen University Hospital, Department of Anesthesiology and Intensive Care Medicine, Hoppe-Seyler-Str. 3, 72076 Tübingen, Germany.
出版信息
J Clin Microbiol. 2008 Feb;46(2):817-20. doi: 10.1128/JCM.01340-07. Epub 2007 Dec 12.
Abstract
A 25-year-old female was admitted to our intensive care unit with septic shock and multiorgan failure caused by extended-spectrum beta-lactamase-producing Escherichia coli originating from the right renal pelvis. A 16-day course of treatment with meropenem reversed the septic condition, but the infection recurred thereafter. The patient recovered fully after therapy was changed to tigecycline.
摘要
一名25岁女性因源于右肾盂的产超广谱β-内酰胺酶大肠杆菌导致的感染性休克和多器官功能衰竭入住我们的重症监护病房。美罗培南治疗16天逆转了感染性休克状态，但此后感染复发。改用替加环素治疗后患者完全康复。
相似文献
1
Treatment with tigecycline of recurrent urosepsis caused by extended-spectrum-beta-lactamase-producing Escherichia coli.用替加环素治疗产超广谱β-内酰胺酶大肠埃希菌引起的复发性泌尿道感染。
J Clin Microbiol. 2008 Feb;46(2):817-20. doi: 10.1128/JCM.01340-07. Epub 2007 Dec 12.
2
Successful treatment with tigecycline of two patients with complicated urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.替加环素成功治疗两例由产超广谱β-内酰胺酶大肠杆菌引起的复杂性尿路感染患者。
J Antimicrob Chemother. 2010 Sep;65(9):2048-9. doi: 10.1093/jac/dkq224. Epub 2010 Jun 16.
3
Are beta-lactams related to higher morbidity and mortality in urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli?β-内酰胺类药物与产超广谱β-内酰胺酶的大肠埃希菌引起的尿路感染的较高发病率和死亡率有关吗？
J Hosp Infect. 2008 Feb;68(2):181-3. doi: 10.1016/j.jhin.2007.11.014. Epub 2008 Jan 14.
4
Therapeutic options for bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli.由产超广谱β-内酰胺酶的大肠杆菌引起的菌血症的治疗选择。
Clin Infect Dis. 2010 Jul 1;51(1):119-20; author reply 120-1. doi: 10.1086/653446.
5
[Evaluation of antibiotic treatments for urinary tract infections in the elderly, especially regarding the effect on extended spectrum β-lactamase producing (ESBL-) Escherichia coli: A comparison between meropenem and alternatives].[老年患者尿路感染抗生素治疗的评估，特别是关于对产超广谱β-内酰胺酶（ESBL-）大肠埃希菌的影响：美罗培南与其他药物的比较]
Nihon Ronen Igakkai Zasshi. 2015;52(2):153-61. doi: 10.3143/geriatrics.52.153.
6
Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial.磷霉素与美罗培南治疗产超广谱β-内酰胺酶大肠埃希菌引起的菌血症性尿路感染（FOREST）：一项研究者发起的随机对照试验研究方案
BMJ Open. 2015 Mar 31;5(3):e007363. doi: 10.1136/bmjopen-2014-007363.
7
Escherichia coli: development of carbapenem resistance during therapy.大肠杆菌：治疗期间碳青霉烯类耐药性的产生
Clin Infect Dis. 2005 May 15;40(10):e84-6. doi: 10.1086/429822. Epub 2005 Apr 13.
8
Increased community-acquired upper urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in children and the efficacy of flomoxef and cefmetazole.产超广谱β-内酰胺酶大肠埃希菌引起的儿童社区获得性上尿路感染增加及氟氧头孢和头孢美唑的疗效。
Clin Exp Nephrol. 2019 Nov;23(11):1306-1314. doi: 10.1007/s10157-019-01775-w. Epub 2019 Aug 19.
9
Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model.使用体外模型测定临床可达到的替加环素血清浓度对产超广谱β-内酰胺酶、AmpCβ-内酰胺酶及对碳青霉烯类药物敏感性降低的大肠埃希菌临床分离株的药效学活性。
J Antimicrob Chemother. 2009 Oct;64(4):824-8. doi: 10.1093/jac/dkp254. Epub 2009 Jul 29.
10
Treatment of lower urinary tract infection caused by multidrug-resistant extended-spectrum-beta-lactamase-producing Escherichia coli with amoxicillin/clavulanate: case report and characterization of the isolate.用阿莫西林/克拉维酸治疗产超广谱β-内酰胺酶的耐多药大肠杆菌引起的下尿路感染：病例报告及分离株特征分析
J Antimicrob Chemother. 2006 Jun;57(6):1262-3. doi: 10.1093/jac/dkl102. Epub 2006 Mar 24.
引用本文的文献
1
Recurrent Urosepsis Following Stent Removal for Ureteral Stones: A Case Report.输尿管结石支架取出术后复发性泌尿道感染：一例报告
Case Rep Urol. 2025 Apr 23;2025:5547651. doi: 10.1155/criu/5547651. eCollection 2025.
2
Pharmacokinetic and pharmacodynamic evaluation of the atypical tetracyclines chelocardin and amidochelocardin in murine infection models.非典型四环素类药物 Chelocardin 和 amidochelocardin 在小鼠感染模型中的药代动力学和药效学评价。
Microbiol Spectr. 2024 Jan 11;12(1):e0128923. doi: 10.1128/spectrum.01289-23. Epub 2023 Dec 4.
3
Role of tigecycline in the treatment of urinary tract infections: a systematic review of published case reports.替加环素在治疗尿路感染中的作用：对已发表病例报告的系统评价
Infez Med. 2022 Dec 1;30(4):516-524. doi: 10.53854/liim-3004-5. eCollection 2022.
4
Role of Tigecycline for the Treatment of Urinary Tract Infections.替加环素在治疗尿路感染中的作用。
J Pharm Technol. 2014 Jun;30(3):87-92. doi: 10.1177/8755122513519332. Epub 2014 Jan 7.
5
Efficacy and safety of tigecycline for complicated urinary tract infection: a systematic review.替加环素治疗复杂性尿路感染的疗效与安全性：一项系统评价
Transl Androl Urol. 2021 Jan;10(1):292-299. doi: 10.21037/tau-20-959.
6
Tigecycline treatment of urinary tract infection and prostatitis: case report and literature review.替加环素治疗尿路感染和前列腺炎：病例报告及文献综述
Can J Hosp Pharm. 2012 May;65(3):209-15. doi: 10.4212/cjhp.v65i3.1144.
7
Ertapenem-induced reduction in valproate levels: case report and review of the literature.厄他培南导致丙戊酸水平降低：病例报告及文献综述
Can J Hosp Pharm. 2010 Jul;63(4):315-22. doi: 10.4212/cjhp.v63i4.936.
8
Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine.氨基糖苷类、多黏菌素 B 和替加环素清除尿液中产碳青霉烯酶肺炎克雷伯菌的比较效果。
Antimicrob Agents Chemother. 2011 Dec;55(12):5893-9. doi: 10.1128/AAC.00387-11. Epub 2011 Oct 3.
9
Current and novel antibiotics against resistant Gram-positive bacteria.当前和新型抗生素治疗耐药革兰阳性菌感染。
Infect Drug Resist. 2008;1:27-44. doi: 10.2147/idr.s3545. Epub 2008 Sep 9.
10
Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease.系统评价和荟萃分析替加环素治疗感染性疾病的有效性和安全性。
Antimicrob Agents Chemother. 2011 Mar;55(3):1162-72. doi: 10.1128/AAC.01402-10. Epub 2010 Dec 20.
本文引用的文献
1
Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role.β-内酰胺类抗生素在严重感染中的持续输注：作用综述
Int J Antimicrob Agents. 2007 Jul;30(1):11-8. doi: 10.1016/j.ijantimicag.2007.02.002. Epub 2007 Apr 17.
2
The pharmacokinetic and pharmacodynamic profile of tigecycline.替加环素的药代动力学和药效学特征。
Clin Infect Dis. 2005 Sep 1;41 Suppl 5:S333-40. doi: 10.1086/431674.
3
Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.通过蒙特卡洛模拟对健康志愿者间歇性给药或持续输注两种剂量美罗培南的药代动力学进行评估。
Antimicrob Agents Chemother. 2005 May;49(5):1881-9. doi: 10.1128/AAC.49.5.1881-1889.2005.
4
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.拯救脓毒症运动：严重脓毒症和脓毒性休克管理指南
Intensive Care Med. 2004 Apr;30(4):536-55. doi: 10.1007/s00134-004-2210-z. Epub 2004 Mar 3.
5
Correlation of meropenem plasma levels with pharmacodynamic requirements in critically ill patients receiving continuous veno-venous hemofiltration.接受持续静脉-静脉血液滤过的重症患者美罗培南血浆水平与药效学要求的相关性
Chemotherapy. 2003 Dec;49(6):280-6. doi: 10.1159/000074527.
6
Correlation between candiduria and departmental antibiotic use.念珠菌尿症与科室抗生素使用之间的相关性。
J Hosp Infect. 2003 Mar;53(3):183-6. doi: 10.1053/jhin.2002.1354.
7
Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration.美罗培南在接受持续血液透析滤过治疗的急性肾衰竭重症患者中的药代动力学。
Antimicrob Agents Chemother. 1998 Sep;42(9):2421-4. doi: 10.1128/AAC.42.9.2421.
Zotero 插件